MedCity News July 2, 2023
CellTrans’s Lantidra is now the first FDA-approved cell therapy for type 1 diabetes. The therapy is made from islet cells sourced from deceased donors.
Insulin independence is a goal of type 1 diabetes drug research and cell therapy holds promise to achieve it. Several biopharmaceutical companies have programs in various stages of development for the autoimmune disorder. A small, little-known biotech company has beaten all of them to win the first FDA approval of a cell therapy for type 1 diabetes.
The company is CellTrans. FDA approval of its cell therapy, known in development as donislecel, covers adults who have type 1 diabetes and are unable to achieve their target glucose levels despite various efforts. Chicago-based CellTrans will commercialize its...
Today's Sponsors
Today's Sponsor